The RASTRIC trial, from organoids to patients and back
Patients with colorectal cancer and a mutation of the RAS gene, have a worse prognosis than patients without this mutation, because their treatment options are limited.
Recently, our lab found a combination of three readily available drugs, that was effective in the lab on CRC organoids with a RAS mutation. The RASTRIC trial is a first-in-human clinical trial to test this new combination.
